Quotient Sciences Quotient Sciences

X

Find Radio Compass News for Apalutamide

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

https://www.globenewswire.com/news-release/2024/01/30/2820140/0/en/Kairos-Pharma-Doses-First-Patient-in-Phase-2-Trial-of-Lead-Drug-Candidate-ENV105-with-Apalutamide-to-Improve-Therapy-Sensitivity-for-Castrate-Resistant-Prostate-Cancer.html

GLOBENEWSWIRE
30 Jan 2024

https://www.newswire.ca/news-releases/erleada-r-apalutamide-240-mg-approved-as-the-only-androgen-receptor-inhibitor-with-a-once-daily-single-tablet-option-in-canada-824240082.html

NEWSWIRE
10 Aug 2023

https://www.prnewswire.com/news-releases/erleada-apalutamide-first-and-only-next-generation-androgen-receptor-inhibitor-with-once-daily-single-tablet-option-now-available-in-the-us-301787489.html

PR NEWSWIRE
03 Apr 2023

https://nation.africa/kenya/news/fda-approves-injectable-drug-for-resistant-hiv-4073822

Amina Wako NATION
03 Jan 2023

https://endpts.com/jj-takes-aurobindo-to-court-over-potential-erleada-generic/

N. DeFeudis ENDPTS
01 Jun 2022

https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-apalutamide-tablets-1649311994.pdf

FDA
06 Apr 2022

https://johnsonandjohnson.gcs-web.com/static-files/28d869b1-8230-473a-a011-e40c8bbcac15

PRESS RELEASE
14 Feb 2022

https://www.pharmaceutical-technology.com/news/jj-split-consumer-health-pharmaceutical/

PHARMACEUTICAL-TECHNOLOGY
15 Nov 2021

https://www.pharmatimes.com/news/nice_changes_its_mind_on_janssens_erleada_1376372

Lucy Parsons PHARMA TIMES
08 Sep 2021

https://www.raps.org/news-and-articles/news-articles/2021/8/fda-finalizes-guidance-on-metastasis-free-survival

Michael Mezher  RAPS
06 Aug 2021

http://www.pharmatimes.com/news/janssens_erleada_maintains_quality_of_life_for_prostate_cancer_patients_1370808

Lucy Parsons PHARMATIMES
27 May 2021

http://www.pharmafile.com/news/578303/nice-rejects-janssens-prostate-cancer-drug-erleada

PHARMAFILE
21 May 2021

https://www.businesswire.com/news/home/20210209005604/en/Janssen-Presents-Results-from-Phase-3-ACIS-Study-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer-Treated-with-Apalutamide%E2%96%BC-and-Abiraterone-Acetate-Combination

BUSINESSWIRE
09 Feb 2021

https://en.prnasia.com/releases/global/kangpu-to-present-two-posters-at-the-2020-american-association-for-cancer-research-aacr-annual-meeting-282967.shtml

PRNASIA
17 Jun 2020

https://www.prnewswire.com/news-releases/janssen-highlights-innovative-oncology-portfolio-and-pipeline-of-oral-biologic-and-cell-therapies-through-asco20-virtual-scientific-program-301067691.html

PRNEWSWIRE
29 May 2020

https://www.fiercepharma.com/pharma/asco-j-j-s-erleada-extends-lives-by-14-months-nonmetastatic-prostate-cancer

Carly Helfand FIERCE PHARMA
13 May 2020

https://www.prnewswire.com/news-releases/erleada-apalutamide-significantly-improved-overall-survival-in-patients-with-non-metastatic-castration-resistant-prostate-cancer-301058911.html

PRNEWSWIRE
13 May 2020

https://www.biospectrumasia.com/news/30/15422/who-to-accelerate-research-and-innovation-for-new-coronavirus.html

BIOSPECTRUMASIA
12 Feb 2020

https://www.fiercepharma.com/marketing/bayer-s-nubeqa-gets-better-chance-at-challenging-pfizer-and-j-j-prostate-cancer-key

Angus Liu FIERCE PHARMA
31 Jan 2020

http://www.pharmafile.com/news/539813/janssens-erleada-expanded-europe-cover-metastatic-hormone-sensitive-prostate-cancer

PHARMAFILE
29 Jan 2020

https://www.businesswire.com/news/home/20200129005336/en/Janssen-Announces-European-Commission-Approval-Expanded-Erleada%C2%AE%E2%96%BC/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==

BUSINESSWIRE
29 Jan 2020

https://www.fiercepharma.com/pharma/esmo-j-j-s-erleada-misses-survival-mark-but-execs-see-reason-to-cheer

Carly Helfand FIERCE PHARMA
28 Sep 2019

http://pharmabiz.com/NewsDetails.aspx?aid=118419&sid=2

PHARMABIZ
27 Sep 2019

http://www.pharmabiz.com/NewsDetails.aspx?aid=118238&sid=2

PHARMABIZ
20 Sep 2019

https://www.biopharmadive.com/news/johnson-erleada-approval-prostate-cancer-pfizer-xtandi/563198/

Jacob Bell BIOPHARMADIVE
19 Sep 2019

https://www.raps.org/news-and-articles/news-articles/2019/9/fda-collaborates-with-health-canada-australia-to

Z. Brennan RAPS
18 Sep 2019

https://www.fiercepharma.com/pharma/asco-pfizer-astellas-xtandi-racks-up-more-data-for-new-prostate-cancer-use

Carly Helfand FIERCE PHARMA
03 Jun 2019

https://www.fiercepharma.com/pharma/asco-j-j-pads-case-for-new-erleada-use-prostate-cancer-survival-data

Carly Helfand FIERCE PHARMA
31 May 2019

https://www.fiercepharma.com/pharma/asco-2019-what-to-watch-for-including-keytruda-lynparza-seagen-and-more

Carly Helfand FIERCE PHARMA
31 May 2019

https://www.fiercepharma.com/marketing/j-j-eyes-prostate-cancer-boost-as-fda-accepts-erleada-for-real-time-review

Carly Helfand FIERCE PHARMA
03 May 2019

https://endpts.com/fda-tags-bayers-prostate-cancer-drug-for-priority-review-as-drugmaker-gears-up-against-rivals/

Amber Tong ENDPTS
30 Apr 2019

https://www.prnewswire.com/news-releases/janssen-submits-application-to-us-fda-seeking-approval-of-erleada-apalutamide-for-patients-with-metastatic-castration-sensitive-prostate-cancer-300840126.html

PR NEWSWIRE
29 Apr 2019

https://www.ema.europa.eu/documents/product-information/erleada-epar-product-information_en.pdf

EMA
22 Mar 2019

http://www.evaluate.com/vantage/articles/news/trial-results/asco-gu-bayer-and-orion-have-their-work-cut-out-darolutamide?mkt_tok=eyJpIjoiT0RKa04yTTVaV1ZoWWpZeCIsInQiOiJ4bnU5VmdUSnBIbWhEdUQ1ZDd4TmQxNTNpY1lLY0taSndKSUpWU0wzNE9memF2TktEM2tSeEhnVVR0dXRIdko1ZGxTQ1hJRHh1YXNCNzA1eHpWUXpuVzZYZWRNVk1CdThEVmh5dGJheU1TZEpxeWhqNnlUb25DaDVkMWM5Y0hXdSJ9

Jacob Plieth EVALUATE PHARMA
16 Feb 2019

https://www.biopharmadive.com/news/new-prostate-cancer-data-puts-bayer-drug-in-line-with-pfizer-jj-rivals/548570/

Andrew Dunn BIOPHARMA DIVE
15 Feb 2019

https://www.reuters.com/article/us-bayer-orion-prostate-cancer/bayer-stresses-drugs-tolerability-in-bid-for-prostate-cancer-market-idUSKCN1Q32YV

Ludwig Burger REUTERS
15 Feb 2019

https://www.fiercepharma.com/pharma/j-j-s-erleada-trial-stops-early-good-news-setting-up-case-for-new-prostate-cancer-nod

Carly Helfand FIERCE PHARMA
31 Jan 2019

https://www.pharmaceutical-technology.com/news/us-idmc-recommends-janssen-erleada-mcspc/

Allie Nawrat PHARMA-TECH
31 Jan 2019

https://endpts.com/jj-scores-another-phiii-win-for-erleada-as-it-continues-to-build-a-blockbuster-franchise/

John Carroll ENDPTS
31 Jan 2019
Pfizer's Xtandi blows by J&J's Erleada with hot start in new prostate cancer